XML 18 R6.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Cash Flows - Unaudited - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Cash flows from operating activities:    
Net loss before noncontrolling interest $ (18,268) $ (21,525)
Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:    
Depreciation expense 67 67
Loss from G42 promissory note early redemption 0 313
Non-cash interest income 0 (100)
Share-based compensation expense 1,932 1,175
Change in fair value of investments 0 (3,044)
Impairment of investments in Anteris Bio, Inc 0 4,245
Changes in assets and liabilities:    
Accounts receivable (140) 173
Prepaid expenses and other current assets (36) 665
Other assets 88 0
Accounts payable and accrued expenses (4,016) 2,270
Other liabilities (125) 0
Net cash used in operating activities (20,482) (16,167)
Cash flows from financing activities:    
Proceeds from sale of Class A common stock and pre-funded warrants, net of offering costs 50,335 0
Proceeds from sale of Class A common stock, net of offering costs 2,463 0
Proceeds from G42 Promissory Note early redemption related to sale of Class A common stock to collaboration partner 0 12,030
Proceeds from debt issuance 0 566
Repayment of notes payable (191) (317)
Net cash provided by financing activities 52,607 12,279
Net increase (decrease) in cash and cash equivalents 32,125 (3,888)
Total cash and cash equivalents, beginning of period 9,446 12,126
Total cash and cash equivalents, end of period 41,571 8,238
Non-cash activities:    
Change in redemption value of noncontrolling interest (214) (1,104)
Reclassification of noncontrolling interest to additional paid-in capital 5,260 0
Related Party    
Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:    
Change in fair value of warrants 173 (406)
Nonrelated Party    
Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:    
Change in fair value of warrants $ (157) $ 0